Exposure‐response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components
- 17 June 2019
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (8) , 1710-1718
Abstract
Aims: Tocilizumab has a direct effect on inflammatory markers. Therefore, composite measures for disease activity assessment in rheumatoid arthritis (RA) using these inflammatory markers may not be suitable for tocilizumab treatment. We used a modelling approach to describe the tocilizumab exposure‐response relationship and to investigate the different dynamics of the individual components of the routinely used continuous composite measures.Methods: Pharmacokinetic (PK), clinical and laboratory data were obtained from a prospective, observational, single‐centre study involving 35 subjects with RA treated with intravenous tocilizumab. A population PK/pharmacodynamic analysis was performed using nonlinear mixed effects models.Results: The population for model development comprised 1086, 1083 and 1082 observations calculated with the disease activity score based on 28 joint (DAS28) and the simplified and clinical disease activity scores (SDAI, CDAI). The tocilizumab exposure‐response relationship was described with an indirect‐response model. Two main groups of individual components were identified based on their different dynamics under tocilizumab treatment: (i) tender and swollen joint counts and patient and evaluator global assessment showed a slower decrease of their baseline value (half‐life: 4.6 weeks, RSE: 24%) and the need for higher serum drug concentration (EC50: 4.60 μg/mL, RSE: 103%, IIV: 359%) than (ii) C‐reactive protein and erythrocyte sedimentation rate (half‐life: 2.3 weeks, RSE 19%; EC50: 0.878 μg/mL, RSE: 41%, IIV: 238%).Conclusion: Our study confirms a different dynamics of the individual components of the most frequently used continuous composite measures under tocilizumab treatment which should be taken into account to avoid misassessment of disease activity.Keywords
This publication has 31 references indexed in Scilit:
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEMComputer Methods and Programs in Biomedicine, 2011
- Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI studyModern Rheumatology, 2010
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- ¿Es la puntuación DAS28 el método más adecuado para estimar la actividad de la artritis reumatoide? Consideracionens clinimétricas y escenarios de simulaciónReumatología Clínica, 2008
- Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE MethodPharmaceutical Research, 2007
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1992